CoChat

PIOGLITAZONE ADJUNCTIVE THERAPY FOR DEPRESSIVE EPISODE OF BIPOLAR DISORDER: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL: Research Article: Pioglitazone for Bipolar Depression

Zeinoddini, Atefeh, Sorayani, Maryam, Hassanzadeh, Elmira, Arbabi, Mohammad, Farokhnia, Mehdi, Salimi, Samrand, Ghaleiha, Ali, Akhondzadeh, Shahin · 2015 · Depression and Anxiety
Cited by 111

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The antidepressive effect of pioglitazone has been noted in patients with major depressive disorder in absence of metabolic syndrome. This study was conducted to evaluate the safety and efficacy of pioglitazone in patients with bipolar depression without concomitant metabolic syndrome or diabetes. METHOD: Forty-eight outpatients with the diagnosis of bipolar I disorder and a major depressive episode participated in a parallel, randomized, double-blind, placebo-controlled trial, and 44 patients underwent 6-week treatment with either pioglitazone (30 mg/day) or placebo as an adjunctive treatment to lithium. Therapeutic serum lithium levels of 0.6-0.8 mEq/L were required for two or more consecutive weeks immediately before starting pioglitazone and during the 6-week study. Patients were evaluated using Hamilton Depression Rating Scale (HDRS) and Young Mania Rating Scale (YMRS) at baseline and weeks 1, 2, 4, and 6. The primary outcome was to evaluate the efficacy of pioglitazone in improving the depressive symptoms. RESULT: General linear model repeated measures showed significant effect for time × treatment interaction on the HDRS scores [F(2.78, 116.65) = 4.77, P = .005]. Significantly greater reduction was observed in HDRS scores in the pioglitazone group than the placebo group from baseline HDRS score at weeks 2, 4, and 6, P = .003, .006, and .006, respectively. No serious adverse event was observed. CONCLUSION: This study showed that pioglitazone could be a tolerable and effective adjunctive therapy for improving depressive symptoms in bipolar disorder without type 2 diabetes or metabolic syndrome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/da.22340

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 26

  1. Calabrese, 2004, Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample, J Clin Psychiatry, 65, 1499, 10.4088/JCP.v65n1109 · DOI · Paper page
  2. Simon, 2007, Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression, J Clin Psychiatry, 68, 1237, 10.4088/JCP.v68n0811 · DOI · Paper page
  3. Nivoli, 2011, New treatment guidelines for acute bipolar depression: a systematic review, J Affect Disord, 129, 14, 10.1016/j.jad.2010.05.018 · DOI · Paper page
  4. Association, 2002, Practice guideline for the treatment of patients with bipolar disorder (revision), Am J Psychiatry, 159, 1
  5. Jick, 2004, Antidepressants and the risk of suicidal behaviors, JAMA, 292, 338, 10.1001/jama.292.3.338 · DOI · Paper page
  6. Yatham, 2009, Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009, Bipolar Disord, 11, 225, 10.1111/j.1399-5618.2009.00672.x · DOI · Paper page
  7. Spiegelman, 1998, PPAR-gamma: adipogenic regulator and thiazolidinedione receptor, Diabetes, 47, 507, 10.2337/diabetes.47.4.507 · DOI · Paper page
  8. Kaiser, 2009, A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis, J Neuroimmunol, 211, 124, 10.1016/j.jneuroim.2009.04.011 · DOI
  9. Miller, 2011, Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease, Ann Pharmacother, 45, 1416, 10.1345/aph.1Q238 · DOI · Paper page
  10. Kemp, 2014, PPAR-gamma agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression, CNS Drugs, 28, 571, 10.1007/s40263-014-0158-2 · DOI · Paper page
  11. Kemp, 2010, Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome, Bipolar Disord, 12, 404, 10.1111/j.1399-5618.2010.00823.x · DOI · Paper page
  12. Kemp, 2009, Antidepressant response associated with pioglitazone: support for an overlapping pathophysiology between major depression and metabolic syndrome, Am J Psychiatry, 166, 619, 10.1176/appi.ajp.2008.08081195 · DOI · Paper page
  13. Koponen, 2008, Metabolic syndrome predisposes to depressive symptoms: a population-based 7-year follow-up study, J Clin Psychiatry, 69, 178, 10.4088/JCP.v69n0202 · DOI · Paper page
  14. Mathew, 2008, Novel drugs and therapeutic targets for severe mood disorders, Neuropsychopharmacology, 33, 2080, 10.1038/sj.npp.1301652 · DOI · Paper page
  15. Salehi-Sadaghiani, 2012, NMDA receptor involvement in antidepressant-like effect of pioglitazone in the forced swimming test in mice, Psychopharmacology, 223, 345, 10.1007/s00213-012-2722-0 · DOI
  16. Sepanjnia, 2012, Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial, Neuropsychopharmacology, 37, 2093, 10.1038/npp.2012.58 · DOI · Paper page
  17. Cuellar, 2005, Distinctions between bipolar and unipolar depression, Clin Psychol Rev, 25, 307, 10.1016/j.cpr.2004.12.002 · DOI · Paper page
  18. Hamilton, 1960, A rating scale for depression, J Neurol Neurosurg Psychiatry, 23, 56, 10.1136/jnnp.23.1.56 · DOI · Paper page
  19. Third Report of the National Cholesterol Education Program (NCEP), 2002, Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143 · DOI · Paper page
  20. Zeinoddini, 2014, L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial, J Psychiat Res, 59, 125, 10.1016/j.jpsychires.2014.08.016 · DOI
  21. Amrollahi, 2011, Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania, J Affect Disord, 129, 327, 10.1016/j.jad.2010.08.015 · DOI
  22. Abolfazli, 2011, Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression, Depress Anxiety, 28, 297, 10.1002/da.20801 · DOI · Paper page
  23. Abbasi, 2012, Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study, J Affect Disord, 141, 308, 10.1016/j.jad.2012.03.033 · DOI · Paper page
  24. Shahmansouri, 2014, A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients, J Affect Disord, 155, 216, 10.1016/j.jad.2013.11.003 · DOI
  25. Sadaghiani, 2011, Antidepressant-like effect of pioglitazone in the forced swimming test in mice: the role of PPAR-gamma receptor and nitric oxide pathway, Behav Brain Res, 224, 336, 10.1016/j.bbr.2011.06.011 · DOI
  26. Vlckova, 2010, Hypoglycaemia with pioglitazone: analysis of data from the prescription-event monitoring study, J Eval Clin Pract, 16, 1124, 10.1111/j.1365-2753.2009.01280.x · DOI · Paper page

Cited by

See all 111

Metadata

Authors
Zeinoddini, A., Sorayani, M., Hassanzadeh, E., Arbabi, M., Farokhnia, M., Salimi, S., Ghaleiha, A., & Akhondzadeh, S.
Venue
Depression and Anxiety
Published
2015-01-23
Volume
32
Issue
3
Pages
167-173
ISSN
1091-4269 (ISSN-L)
OpenAlex
W1911808475
Cited by
111
References
6
FWCI
11.34
Type
journal article
Language
en
Open access
closed
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 221 d)
Funders
Tehran University of Medical Sciences (16043)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.